This clinical-stage biotech specializing in blood disorders reported a notable insider sale amid strong recent stock performance.
On Jan. 2, Rahul Khara, the chief legal officer of Disc Medicine (IRON 1.45%), exercised and immediately sold 6,500 shares in a derivative transaction valued at approximately $511,472, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 6,500 |
| Transaction value | $511,471.8 |
| Post-transaction shares (direct) | 37,793 |
| Post-transaction value (direct ownership) | $2.99 million |
Transaction value based on SEC Form 4 weighted average purchase price; post-transaction value based on the Jan. 2 market close.
Key questions
- How significant was this transaction relative to Khara’s prior activity?
The 6,500-share exercise and sale aligns with the recent median administrative sale size of 7,000 shares, representing 14.7% of direct holdings, which is consistent with the 13.28% median for the past year. - What does the derivative context indicate about insider intent?
This transaction was a structured, non-discretionary sale of shares acquired through option exercise, rather than an open-market discretionary sale. - How did this sale affect Khara’s remaining capacity and ownership?
Direct holdings declined to 37,793 shares; Khara also reported holding stock options underlying 22,270 shares. - What is the market context for this transaction?
The transaction occurred at a weighted average price of $78.69 per share; over the trailing year, Disc Medicine shares delivered a 26.6% return as of the transaction date.
Company overview
| Metric | Value |
|---|---|
| Price (as of Jan. 2) | $78.69 |
| Market capitalization | $2.95 billion |
| Net income (TTM) | ($181.11 million) |
| 1-year price change | 26.6% |
* 1-year price change calculated using Jan. 2, 2026 as the reference date.
Company snapshot
- Disc Medicine, Inc. develops and advances clinical-stage therapeutic candidates targeting hematologic diseases, with a focus on red blood cell biology, heme biosynthesis, and iron homeostasis.
- The company operates a biotechnology business model, investing in research and development to bring novel therapies through clinical trials toward regulatory approval and future commercialization.
- Primary customers include healthcare providers and institutions treating patients with serious hematologic disorders, particularly those with unmet medical needs in red blood cell and iron regulation.
Disc Medicine, Inc. is a clinical-stage biotechnology company specializing in innovative treatments for hematologic diseases. Leveraging expertise in red blood cell biology, primarily heme biosynthesis and iron homeostasis, the company is building a portfolio of therapeutic candidates.
What this transaction means for investors
This sale came from a pre-scheduled Rule 10b5-1 plan and followed an option exercise, making it an administrative move rather than a discretionary bet against the business. That context matters because Disc is operating from a position of financial strength. The company ended the third quarter with…
Read More: What Investors Should Know About a $511K Disc Medicine Insider Sale and a
